Find out how you can get the best content on Seeking Alpha here. We are short shares of Principia Biopharma (NASDAQ: PRNB), a company whose $2 billion valuation rests on a single obscure molecule ...

SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to ...

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies ...

Patient improvement during Phase 2 trial of Principia's drug likely caused not by the drug but by regression to the mean. We believe secondary-endpoint results were likely not statistically ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

SAN FRANCISCO, Oct. 29, 2012 -- SAN FRANCISCO, Oct. 29, 2012 /PRNewswire/ -- Principia Biopharma, Inc., a privately-held biopharmaceutical company focused on advancing best-in-class medicines in ...

Sanofi has struck a deal to buy its partner Principia Biopharma for $3.7 billion in cash. The takeover will give Sanofi full ownership of a BTK inhibitor it moved into a raft of phase 3 multiple ...

March 11, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant ...

SOUTH SAN FRANCISCO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated ...

Guardant Health has announced a strategic collaboration with Principia Biopharma to monitor the response of patients enrolled in clinical trials for Principia's FGFR inhibitor, PRN1371. Principia ...

Principia Biopharma Inc., which is developing drugs to treat cancer and inflammatory diseases, said it secured a $12.5 million second tranche of its Series A financing. It will use the proceeds to ...

Principia Biopharma Inc. said its initial public offering raised about $106 million to fund development of oral therapeutics focused on immunology and oncology. The South San Francisco ...